Share on LinkedInShare on LinkedIn

ARTICLE · 25 SEPTEMBER 2024

AI: EMA Publishes Guiding Principles On The Use Of Large Language Models (LLMs)

Arnold & Porter
Arnold & Porter
Contributor
Arnold & Porter

Arnold & Porter

With over 1,000 lawyers across 16 offices worldwide, Arnold & Porter is renowned for its...

View firm profile
Explore more from Arnold & Porter

On 5 September 2024, the European Medicines Agency (EMA) and the Heads of Medicine Agencies (HMA) published a guidance document (the Guidance) with general principles and recommendations on the use of large language models (LLMs) in regulatory science and the regulation of medicinal products.

United StatesTechnology

On 5 September 2024, the European Medicines Agency (EMA) and the Heads of Medicine Agencies (HMA) published a guidance document (the Guidance) with general principles and recommendations on the use of large language models (LLMs) in regulatory science and the regulation of medicinal products. The guiding principles for users are also summarised in a one-page factsheet.

While the Guidance is aimed at the European Union (EU) regulatory authorities, it is instructive for companies active in the Life Sciences sector. It provides useful insight into how regulators will approach the use of LLMs in their regulatory activities, the risks they have identified and how these risks can be mitigated.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from